Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)
Identifieur interne : 001486 ( PascalFrancis/Corpus ); précédent : 001485; suivant : 001487Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)
Auteurs : Adolfo Diez-Perez ; Frederick H. Hooven ; Jonathan D. Adachi ; Silvano Adami ; Frederick A. Anderson ; Steven Boonen ; Roland Chapurlat ; Juliet E. Compston ; Cyrus Cooper ; Pierre Delmas ; Susan L. Greenspan ; Andrea Z. Lacroix ; Robert Lindsay ; J. Coen Netelenbos ; Johannes Pfeilschifter ; Christian Roux ; Kenneth G. Saag ; Philip Sambrook ; Stuart Silverman ; Ethel S. Siris ; Nelson B. Watts ; Grigor Nika ; Stephen H. GehlbachSource :
- Bone : (New York, NY) [ 8756-3282 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose: To determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors. Methods: The Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status. Results: Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45-52% versus 62-65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5-3.1 ) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4-1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment. Conclusions: The likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 12-0170990 INIST |
|---|---|
| ET : | Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW) |
| AU : | DIEZ-PEREZ (Adolfo); HOOVEN (Frederick H.); ADACHI (Jonathan D.); ADAMI (Silvano); ANDERSON (Frederick A.); BOONEN (Steven); CHAPURLAT (Roland); COMPSTON (Juliet E.); COOPER (Cyrus); DELMAS (Pierre); GREENSPAN (Susan L.); LACROIX (Andrea Z.); LINDSAY (Robert); COEN NETELENBOS (J.); PFEILSCHIFTER (Johannes); ROUX (Christian); SAAG (Kenneth G.); SAMBROOK (Philip); SILVERMAN (Stuart); SIRIS (Ethel S.); WATTS (Nelson B.); NIKA (Grigor); GEHLBACH (Stephen H.) |
| AF : | Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III/Barcelona/Espagne (1 aut.); Center for Outcomes Research, University of Massachusetts Medical School/Worcester, MA/Etats-Unis (2 aut., 5 aut., 22 aut., 23 aut.); St Joseph's Hospital, McMaster University/Hamilton, ON/Canada (3 aut.); Department of Rheumatology, University of Verona, Ospedale/Verona, Valeggio/Italie (4 aut.); Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven/Leuven/Belgique (6 aut.); INSERM Research Unit 831, Universite de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot/Lyon/France (7 aut.); University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital/Cambridge/Royaume-Uni (8 aut.); MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford/Oxford/Royaume-Uni (9 aut.); Hôpital Edouard Herriot/Lyon/France (10 aut.); University of Pittsburgh/PA/Etats-Unis (11 aut.); Fred Hutchinson Cancer Research Center/Seattle, WA/Etats-Unis (12 aut.); Regional Bone Center, Helen Hayes Hospital/West Haverstraw, NY/Etats-Unis (13 aut.); Department of Endocrinology, VU University Medical Center/Amsterdam/Pays-Bas (14 aut.); Alfried Krupp Krankenhaus, Department of Internal Medicine III/Essen/Allemagne (15 aut.); Paris Descartes University, Cochin Hospital/Paris/France (16 aut.); University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology/Birmingham, AL/Etats-Unis (17 aut.); University of Sydney-Royal North Shore Hospital, St. Leonards/Sydney, NSW/Australie (18 aut.); Cedars-Sinai Medical Center/Los Angeles, CA/Etats-Unis (19 aut.); Columbia University Medical Center/New York, NY/Etats-Unis (20 aut.); Bone Health and Osteoporosis Center, University of Cincinnati/Cincinnati, OH/Etats-Unis (21 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Bone : (New York, NY); ISSN 8756-3282; Pays-Bas; Da. 2011; Vol. 49; No. 3; Pp. 493-498; Bibl. 26 ref. |
| LA : | Anglais |
| EA : | Purpose: To determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors. Methods: The Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status. Results: Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45-52% versus 62-65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5-3.1 ) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4-1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment. Conclusions: The likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis. |
| CC : | 002A16; 002B15A; 002B16H |
| FD : | Traitement régional; Ostéoporose; Femme; Fracture; Facteur risque; Prévention; Morphologie |
| FG : | Homme; Pathologie du système ostéoarticulaire; Traumatisme |
| ED : | Regional treatment; Osteoporosis; Woman; Fracture; Risk factor; Prevention; Morphology |
| EG : | Human; Diseases of the osteoarticular system; Trauma |
| SD : | Tratamiento regional; Osteoporosis; Mujer; Fractura; Factor riesgo; Prevención; Morfología |
| LO : | INIST-19041.354000194653440220 |
| ID : | 12-0170990 |
Links to Exploration step
Pascal:12-0170990Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)</title><author><name sortKey="Diez Perez, Adolfo" sort="Diez Perez, Adolfo" uniqKey="Diez Perez A" first="Adolfo" last="Diez-Perez">Adolfo Diez-Perez</name><affiliation><inist:fA14 i1="01"><s1>Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hooven, Frederick H" sort="Hooven, Frederick H" uniqKey="Hooven F" first="Frederick H." last="Hooven">Frederick H. Hooven</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Adachi, Jonathan D" sort="Adachi, Jonathan D" uniqKey="Adachi J" first="Jonathan D." last="Adachi">Jonathan D. Adachi</name><affiliation><inist:fA14 i1="03"><s1>St Joseph's Hospital, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Adami, Silvano" sort="Adami, Silvano" uniqKey="Adami S" first="Silvano" last="Adami">Silvano Adami</name><affiliation><inist:fA14 i1="04"><s1>Department of Rheumatology, University of Verona, Ospedale</s1><s2>Verona, Valeggio</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Frederick A" sort="Anderson, Frederick A" uniqKey="Anderson F" first="Frederick A." last="Anderson">Frederick A. Anderson</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name><affiliation><inist:fA14 i1="05"><s1>Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven</s1><s2>Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chapurlat, Roland" sort="Chapurlat, Roland" uniqKey="Chapurlat R" first="Roland" last="Chapurlat">Roland Chapurlat</name><affiliation><inist:fA14 i1="06"><s1>INSERM Research Unit 831, Universite de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Compston, Juliet E" sort="Compston, Juliet E" uniqKey="Compston J" first="Juliet E." last="Compston">Juliet E. Compston</name><affiliation><inist:fA14 i1="07"><s1>University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name><affiliation><inist:fA14 i1="08"><s1>MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Delmas, Pierre" sort="Delmas, Pierre" uniqKey="Delmas P" first="Pierre" last="Delmas">Pierre Delmas</name><affiliation><inist:fA14 i1="09"><s1>Hôpital Edouard Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name><affiliation><inist:fA14 i1="10"><s1>University of Pittsburgh</s1><s2>PA</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z." last="Lacroix">Andrea Z. Lacroix</name><affiliation><inist:fA14 i1="11"><s1>Fred Hutchinson Cancer Research Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name><affiliation><inist:fA14 i1="12"><s1>Regional Bone Center, Helen Hayes Hospital</s1><s2>West Haverstraw, NY</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coen Netelenbos, J" sort="Coen Netelenbos, J" uniqKey="Coen Netelenbos J" first="J." last="Coen Netelenbos">J. Coen Netelenbos</name><affiliation><inist:fA14 i1="13"><s1>Department of Endocrinology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pfeilschifter, Johannes" sort="Pfeilschifter, Johannes" uniqKey="Pfeilschifter J" first="Johannes" last="Pfeilschifter">Johannes Pfeilschifter</name><affiliation><inist:fA14 i1="14"><s1>Alfried Krupp Krankenhaus, Department of Internal Medicine III</s1><s2>Essen</s2><s3>DEU</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Roux, Christian" sort="Roux, Christian" uniqKey="Roux C" first="Christian" last="Roux">Christian Roux</name><affiliation><inist:fA14 i1="15"><s1>Paris Descartes University, Cochin Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G." last="Saag">Kenneth G. Saag</name><affiliation><inist:fA14 i1="16"><s1>University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology</s1><s2>Birmingham, AL</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sambrook, Philip" sort="Sambrook, Philip" uniqKey="Sambrook P" first="Philip" last="Sambrook">Philip Sambrook</name><affiliation><inist:fA14 i1="17"><s1>University of Sydney-Royal North Shore Hospital, St. Leonards</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Silverman, Stuart" sort="Silverman, Stuart" uniqKey="Silverman S" first="Stuart" last="Silverman">Stuart Silverman</name><affiliation><inist:fA14 i1="18"><s1>Cedars-Sinai Medical Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Siris, Ethel S" sort="Siris, Ethel S" uniqKey="Siris E" first="Ethel S." last="Siris">Ethel S. Siris</name><affiliation><inist:fA14 i1="19"><s1>Columbia University Medical Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name><affiliation><inist:fA14 i1="20"><s1>Bone Health and Osteoporosis Center, University of Cincinnati</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Nika, Grigor" sort="Nika, Grigor" uniqKey="Nika G" first="Grigor" last="Nika">Grigor Nika</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gehlbach, Stephen H" sort="Gehlbach, Stephen H" uniqKey="Gehlbach S" first="Stephen H." last="Gehlbach">Stephen H. Gehlbach</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0170990</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 12-0170990 INIST</idno><idno type="RBID">Pascal:12-0170990</idno><idno type="wicri:Area/PascalFrancis/Corpus">001486</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)</title><author><name sortKey="Diez Perez, Adolfo" sort="Diez Perez, Adolfo" uniqKey="Diez Perez A" first="Adolfo" last="Diez-Perez">Adolfo Diez-Perez</name><affiliation><inist:fA14 i1="01"><s1>Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hooven, Frederick H" sort="Hooven, Frederick H" uniqKey="Hooven F" first="Frederick H." last="Hooven">Frederick H. Hooven</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Adachi, Jonathan D" sort="Adachi, Jonathan D" uniqKey="Adachi J" first="Jonathan D." last="Adachi">Jonathan D. Adachi</name><affiliation><inist:fA14 i1="03"><s1>St Joseph's Hospital, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Adami, Silvano" sort="Adami, Silvano" uniqKey="Adami S" first="Silvano" last="Adami">Silvano Adami</name><affiliation><inist:fA14 i1="04"><s1>Department of Rheumatology, University of Verona, Ospedale</s1><s2>Verona, Valeggio</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Frederick A" sort="Anderson, Frederick A" uniqKey="Anderson F" first="Frederick A." last="Anderson">Frederick A. Anderson</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name><affiliation><inist:fA14 i1="05"><s1>Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven</s1><s2>Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chapurlat, Roland" sort="Chapurlat, Roland" uniqKey="Chapurlat R" first="Roland" last="Chapurlat">Roland Chapurlat</name><affiliation><inist:fA14 i1="06"><s1>INSERM Research Unit 831, Universite de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Compston, Juliet E" sort="Compston, Juliet E" uniqKey="Compston J" first="Juliet E." last="Compston">Juliet E. Compston</name><affiliation><inist:fA14 i1="07"><s1>University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name><affiliation><inist:fA14 i1="08"><s1>MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Delmas, Pierre" sort="Delmas, Pierre" uniqKey="Delmas P" first="Pierre" last="Delmas">Pierre Delmas</name><affiliation><inist:fA14 i1="09"><s1>Hôpital Edouard Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Greenspan, Susan L" sort="Greenspan, Susan L" uniqKey="Greenspan S" first="Susan L." last="Greenspan">Susan L. Greenspan</name><affiliation><inist:fA14 i1="10"><s1>University of Pittsburgh</s1><s2>PA</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z." last="Lacroix">Andrea Z. Lacroix</name><affiliation><inist:fA14 i1="11"><s1>Fred Hutchinson Cancer Research Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lindsay, Robert" sort="Lindsay, Robert" uniqKey="Lindsay R" first="Robert" last="Lindsay">Robert Lindsay</name><affiliation><inist:fA14 i1="12"><s1>Regional Bone Center, Helen Hayes Hospital</s1><s2>West Haverstraw, NY</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coen Netelenbos, J" sort="Coen Netelenbos, J" uniqKey="Coen Netelenbos J" first="J." last="Coen Netelenbos">J. Coen Netelenbos</name><affiliation><inist:fA14 i1="13"><s1>Department of Endocrinology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pfeilschifter, Johannes" sort="Pfeilschifter, Johannes" uniqKey="Pfeilschifter J" first="Johannes" last="Pfeilschifter">Johannes Pfeilschifter</name><affiliation><inist:fA14 i1="14"><s1>Alfried Krupp Krankenhaus, Department of Internal Medicine III</s1><s2>Essen</s2><s3>DEU</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Roux, Christian" sort="Roux, Christian" uniqKey="Roux C" first="Christian" last="Roux">Christian Roux</name><affiliation><inist:fA14 i1="15"><s1>Paris Descartes University, Cochin Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G." last="Saag">Kenneth G. Saag</name><affiliation><inist:fA14 i1="16"><s1>University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology</s1><s2>Birmingham, AL</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sambrook, Philip" sort="Sambrook, Philip" uniqKey="Sambrook P" first="Philip" last="Sambrook">Philip Sambrook</name><affiliation><inist:fA14 i1="17"><s1>University of Sydney-Royal North Shore Hospital, St. Leonards</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Silverman, Stuart" sort="Silverman, Stuart" uniqKey="Silverman S" first="Stuart" last="Silverman">Stuart Silverman</name><affiliation><inist:fA14 i1="18"><s1>Cedars-Sinai Medical Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Siris, Ethel S" sort="Siris, Ethel S" uniqKey="Siris E" first="Ethel S." last="Siris">Ethel S. Siris</name><affiliation><inist:fA14 i1="19"><s1>Columbia University Medical Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Watts, Nelson B" sort="Watts, Nelson B" uniqKey="Watts N" first="Nelson B." last="Watts">Nelson B. Watts</name><affiliation><inist:fA14 i1="20"><s1>Bone Health and Osteoporosis Center, University of Cincinnati</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Nika, Grigor" sort="Nika, Grigor" uniqKey="Nika G" first="Grigor" last="Nika">Grigor Nika</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gehlbach, Stephen H" sort="Gehlbach, Stephen H" uniqKey="Gehlbach S" first="Stephen H." last="Gehlbach">Stephen H. Gehlbach</name><affiliation><inist:fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Bone : (New York, NY)</title><title level="j" type="abbreviated">Bone : (NY NY)</title><idno type="ISSN">8756-3282</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bone : (New York, NY)</title><title level="j" type="abbreviated">Bone : (NY NY)</title><idno type="ISSN">8756-3282</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Fracture</term><term>Morphology</term><term>Osteoporosis</term><term>Prevention</term><term>Regional treatment</term><term>Risk factor</term><term>Woman</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Traitement régional</term><term>Ostéoporose</term><term>Femme</term><term>Fracture</term><term>Facteur risque</term><term>Prévention</term><term>Morphologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors. Methods: The Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status. Results: Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45-52% versus 62-65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5-3.1 ) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4-1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment. Conclusions: The likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>8756-3282</s0></fA01><fA03 i2="1"><s0>Bone : (NY NY)</s0></fA03><fA05><s2>49</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)</s1></fA08><fA11 i1="01" i2="1"><s1>DIEZ-PEREZ (Adolfo)</s1></fA11><fA11 i1="02" i2="1"><s1>HOOVEN (Frederick H.)</s1></fA11><fA11 i1="03" i2="1"><s1>ADACHI (Jonathan D.)</s1></fA11><fA11 i1="04" i2="1"><s1>ADAMI (Silvano)</s1></fA11><fA11 i1="05" i2="1"><s1>ANDERSON (Frederick A.)</s1></fA11><fA11 i1="06" i2="1"><s1>BOONEN (Steven)</s1></fA11><fA11 i1="07" i2="1"><s1>CHAPURLAT (Roland)</s1></fA11><fA11 i1="08" i2="1"><s1>COMPSTON (Juliet E.)</s1></fA11><fA11 i1="09" i2="1"><s1>COOPER (Cyrus)</s1></fA11><fA11 i1="10" i2="1"><s1>DELMAS (Pierre)</s1></fA11><fA11 i1="11" i2="1"><s1>GREENSPAN (Susan L.)</s1></fA11><fA11 i1="12" i2="1"><s1>LACROIX (Andrea Z.)</s1></fA11><fA11 i1="13" i2="1"><s1>LINDSAY (Robert)</s1></fA11><fA11 i1="14" i2="1"><s1>COEN NETELENBOS (J.)</s1></fA11><fA11 i1="15" i2="1"><s1>PFEILSCHIFTER (Johannes)</s1></fA11><fA11 i1="16" i2="1"><s1>ROUX (Christian)</s1></fA11><fA11 i1="17" i2="1"><s1>SAAG (Kenneth G.)</s1></fA11><fA11 i1="18" i2="1"><s1>SAMBROOK (Philip)</s1></fA11><fA11 i1="19" i2="1"><s1>SILVERMAN (Stuart)</s1></fA11><fA11 i1="20" i2="1"><s1>SIRIS (Ethel S.)</s1></fA11><fA11 i1="21" i2="1"><s1>WATTS (Nelson B.)</s1></fA11><fA11 i1="22" i2="1"><s1>NIKA (Grigor)</s1></fA11><fA11 i1="23" i2="1"><s1>GEHLBACH (Stephen H.)</s1></fA11><fA14 i1="01"><s1>Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Center for Outcomes Research, University of Massachusetts Medical School</s1><s2>Worcester, MA</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>22 aut.</sZ><sZ>23 aut.</sZ></fA14><fA14 i1="03"><s1>St Joseph's Hospital, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Rheumatology, University of Verona, Ospedale</s1><s2>Verona, Valeggio</s2><s3>ITA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven</s1><s2>Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>INSERM Research Unit 831, Universite de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Hôpital Edouard Herriot</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>University of Pittsburgh</s1><s2>PA</s2><s3>USA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Fred Hutchinson Cancer Research Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>12 aut.</sZ></fA14><fA14 i1="12"><s1>Regional Bone Center, Helen Hayes Hospital</s1><s2>West Haverstraw, NY</s2><s3>USA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="13"><s1>Department of Endocrinology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>14 aut.</sZ></fA14><fA14 i1="14"><s1>Alfried Krupp Krankenhaus, Department of Internal Medicine III</s1><s2>Essen</s2><s3>DEU</s3><sZ>15 aut.</sZ></fA14><fA14 i1="15"><s1>Paris Descartes University, Cochin Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>16 aut.</sZ></fA14><fA14 i1="16"><s1>University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology</s1><s2>Birmingham, AL</s2><s3>USA</s3><sZ>17 aut.</sZ></fA14><fA14 i1="17"><s1>University of Sydney-Royal North Shore Hospital, St. Leonards</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>18 aut.</sZ></fA14><fA14 i1="18"><s1>Cedars-Sinai Medical Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></fA14><fA14 i1="19"><s1>Columbia University Medical Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>20 aut.</sZ></fA14><fA14 i1="20"><s1>Bone Health and Osteoporosis Center, University of Cincinnati</s1><s2>Cincinnati, OH</s2><s3>USA</s3><sZ>21 aut.</sZ></fA14><fA20><s1>493-498</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>19041</s2><s5>354000194653440220</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>26 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0170990</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Bone : (New York, NY)</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Purpose: To determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors. Methods: The Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status. Results: Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45-52% versus 62-65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5-3.1 ) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4-1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment. Conclusions: The likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.</s0></fC01><fC02 i1="01" i2="X"><s0>002A16</s0></fC02><fC02 i1="02" i2="X"><s0>002B15A</s0></fC02><fC02 i1="03" i2="X"><s0>002B16H</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Traitement régional</s0><s5>07</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Regional treatment</s0><s5>07</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Tratamiento regional</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Ostéoporose</s0><s5>08</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Osteoporosis</s0><s5>08</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Osteoporosis</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Femme</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Woman</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Mujer</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Fracture</s0><s5>14</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Fracture</s0><s5>14</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Fractura</s0><s5>14</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Facteur risque</s0><s5>15</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Risk factor</s0><s5>15</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>15</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Prévention</s0><s5>16</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Prevention</s0><s5>16</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Prevención</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Morphologie</s0><s5>17</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Morphology</s0><s5>17</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Morfología</s0><s5>17</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Traumatisme</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Trauma</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Traumatismo</s0><s5>38</s5></fC07><fN21><s1>129</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 12-0170990 INIST</NO><ET>Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)</ET><AU>DIEZ-PEREZ (Adolfo); HOOVEN (Frederick H.); ADACHI (Jonathan D.); ADAMI (Silvano); ANDERSON (Frederick A.); BOONEN (Steven); CHAPURLAT (Roland); COMPSTON (Juliet E.); COOPER (Cyrus); DELMAS (Pierre); GREENSPAN (Susan L.); LACROIX (Andrea Z.); LINDSAY (Robert); COEN NETELENBOS (J.); PFEILSCHIFTER (Johannes); ROUX (Christian); SAAG (Kenneth G.); SAMBROOK (Philip); SILVERMAN (Stuart); SIRIS (Ethel S.); WATTS (Nelson B.); NIKA (Grigor); GEHLBACH (Stephen H.)</AU><AF>Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III/Barcelona/Espagne (1 aut.); Center for Outcomes Research, University of Massachusetts Medical School/Worcester, MA/Etats-Unis (2 aut., 5 aut., 22 aut., 23 aut.); St Joseph's Hospital, McMaster University/Hamilton, ON/Canada (3 aut.); Department of Rheumatology, University of Verona, Ospedale/Verona, Valeggio/Italie (4 aut.); Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven/Leuven/Belgique (6 aut.); INSERM Research Unit 831, Universite de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot/Lyon/France (7 aut.); University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital/Cambridge/Royaume-Uni (8 aut.); MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford/Oxford/Royaume-Uni (9 aut.); Hôpital Edouard Herriot/Lyon/France (10 aut.); University of Pittsburgh/PA/Etats-Unis (11 aut.); Fred Hutchinson Cancer Research Center/Seattle, WA/Etats-Unis (12 aut.); Regional Bone Center, Helen Hayes Hospital/West Haverstraw, NY/Etats-Unis (13 aut.); Department of Endocrinology, VU University Medical Center/Amsterdam/Pays-Bas (14 aut.); Alfried Krupp Krankenhaus, Department of Internal Medicine III/Essen/Allemagne (15 aut.); Paris Descartes University, Cochin Hospital/Paris/France (16 aut.); University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology/Birmingham, AL/Etats-Unis (17 aut.); University of Sydney-Royal North Shore Hospital, St. Leonards/Sydney, NSW/Australie (18 aut.); Cedars-Sinai Medical Center/Los Angeles, CA/Etats-Unis (19 aut.); Columbia University Medical Center/New York, NY/Etats-Unis (20 aut.); Bone Health and Osteoporosis Center, University of Cincinnati/Cincinnati, OH/Etats-Unis (21 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Bone : (New York, NY); ISSN 8756-3282; Pays-Bas; Da. 2011; Vol. 49; No. 3; Pp. 493-498; Bibl. 26 ref.</SO><LA>Anglais</LA><EA>Purpose: To determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors. Methods: The Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status. Results: Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45-52% versus 62-65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5-3.1 ) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4-1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment. Conclusions: The likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.</EA><CC>002A16; 002B15A; 002B16H</CC><FD>Traitement régional; Ostéoporose; Femme; Fracture; Facteur risque; Prévention; Morphologie</FD><FG>Homme; Pathologie du système ostéoarticulaire; Traumatisme</FG><ED>Regional treatment; Osteoporosis; Woman; Fracture; Risk factor; Prevention; Morphology</ED><EG>Human; Diseases of the osteoarticular system; Trauma</EG><SD>Tratamiento regional; Osteoporosis; Mujer; Fractura; Factor riesgo; Prevención; Morfología</SD><LO>INIST-19041.354000194653440220</LO><ID>12-0170990</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001486 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001486 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:12-0170990
|texte= Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)
}}
| This area was generated with Dilib version V0.6.33. |  |